Roche Diagnostics ranked #1 in overall service performance in independent survey of U.S. clinical laboratories

  Roche Diagnostics ranked #1 in overall service performance in independent
                     survey of U.S. clinical laboratories

2013 IMV ServiceTrak report gives Roche top rankings in chemistry and
immunoassay testing categories

PR Newswire

INDIANAPOLIS, July 1, 2013

INDIANAPOLIS, July 1, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY)
announced today that its U.S. Diagnostics unit was ranked number one in
overall service performance by clinical laboratories in the 2013 ServiceTrakā„¢
Clinical Report. The report was issued by IMV Ltd, an independent firm that
produces an annual series of proprietary reports derived from extensive phone
surveys of clinical laboratory professionals to determine their level of
satisfaction with the service they receive from the manufacturers of their
clinical diagnostic equipment.

In the report, customers rated the Roche Support Network first in overall
service performance in both chemistry and immunoassay testing categories.
Report results are based on questions related to 46 attributes assessing the
level of satisfaction among laboratory professionals with a manufacturer, its
system(s) and its service performance.

"We are honored to be recognized by laboratories for our service performance,"
said Reg Stump, vice president, Roche Support Network. "Service plays a key
role in helping labs stay up and running so they can deliver reliable test
results to physicians and patients. This recognition indicates to us that our
efforts to help labs maximize their productivity are having a positive
impact."

About IMV
IMV (www.imvinfo.com) is a market research consulting firm founded in 1977
specializing in clinical diagnostics, diagnostic imaging, patient monitoring
and other advanced healthcare technology markets. IMV's marketing and sales
consulting services, in combination with our census databases of U.S. in-vitro
diagnostic testing, diagnostic imaging sites and radiation oncology
facilities, provide clients with valuable market information in strategic
planning, sales initiatives, customer satisfaction and product development.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company, with truly differentiated medicines in
oncology, infectious diseases, inflammation, metabolism and neuroscience.
Roche is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. Roche's personalized
healthcare strategy aims at providing medicines and diagnostic tools that
enable tangible improvements in the health, quality of life and survival of
patients. In 2012 Roche had over 82,000 employees worldwide and invested over
8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss
francs. Genentech, in the United States, is a wholly owned member of the Roche
Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For
more information, please visit www.roche.com or www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Todd Siesky
Director, Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN
(317) 521-3966
todd.siesky@roche.com



SOURCE Roche Diagnostics

Website: http://www.roche.com
 
Press spacebar to pause and continue. Press esc to stop.